JPWO2019155067A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019155067A5 JPWO2019155067A5 JP2020533287A JP2020533287A JPWO2019155067A5 JP WO2019155067 A5 JPWO2019155067 A5 JP WO2019155067A5 JP 2020533287 A JP2020533287 A JP 2020533287A JP 2020533287 A JP2020533287 A JP 2020533287A JP WO2019155067 A5 JPWO2019155067 A5 JP WO2019155067A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- binding portion
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 50
- 102000036639 antigens Human genes 0.000 claims description 50
- 108091007433 antigens Proteins 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 claims description 7
- 101001138126 Homo sapiens Immunoglobulin kappa variable 1-16 Proteins 0.000 claims description 7
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 claims description 7
- 102100020946 Immunoglobulin kappa variable 1-16 Human genes 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 3
- -1 radioisotope Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 6
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000031852 Gastrointestinal stromal cancer Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010073360 Appendix cancer Diseases 0.000 claims 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000005443 oral cavity cancer Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000008006 pharynx cancer Diseases 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 description 12
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 10
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023188151A JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802201.2A GB201802201D0 (en) | 2018-02-09 | 2018-02-09 | Binding agents |
| GB1802201.2 | 2018-02-09 | ||
| GBGB1806468.3A GB201806468D0 (en) | 2018-02-09 | 2018-04-20 | C-KIT Binding agents |
| GB1806468.3 | 2018-04-20 | ||
| PCT/EP2019/053331 WO2019155067A1 (en) | 2018-02-09 | 2019-02-11 | C-kit antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188151A Division JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513323A JP2021513323A (ja) | 2021-05-27 |
| JPWO2019155067A5 true JPWO2019155067A5 (de) | 2023-05-16 |
| JP7449861B2 JP7449861B2 (ja) | 2024-03-14 |
Family
ID=61731463
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533287A Active JP7449861B2 (ja) | 2018-02-09 | 2019-02-11 | Ｃ－ｋｉｔ抗体 |
| JP2023188151A Pending JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188151A Pending JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10611838B2 (de) |
| EP (1) | EP3749694A1 (de) |
| JP (2) | JP7449861B2 (de) |
| CN (2) | CN117510635A (de) |
| AU (2) | AU2019219312B2 (de) |
| CA (1) | CA3085246A1 (de) |
| GB (2) | GB201802201D0 (de) |
| IL (1) | IL275657A (de) |
| SG (1) | SG11202005357QA (de) |
| WO (1) | WO2019155067A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201802201D0 (en) | 2018-02-09 | 2018-03-28 | Ultrahuman Five Ltd | Binding agents |
| KR20210063782A (ko) * | 2019-11-25 | 2021-06-02 | 주식회사 노벨티노빌리티 | c-kit에 대한 항체 및 이의 용도 |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| AU2022297367A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023164744A1 (en) * | 2022-03-01 | 2023-09-07 | CSL Innovation Pty Ltd | Methods of bone marrow conditioning |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2023240272A2 (en) * | 2022-06-09 | 2023-12-14 | Santa Ana Bio, Inc. | Antibodies targeting c-kit and/or siglec and uses thereof |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024023273A1 (en) * | 2022-07-28 | 2024-02-01 | Granular Therapeutics Limited | Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101171263A (zh) | 2005-03-04 | 2008-04-30 | 比奥根艾迪克Ma公司 | 通过合理修饰互补决定区残基使免疫球蛋白可变区人源化的方法 |
| ES2531933T3 (es) | 2006-06-30 | 2015-03-20 | Novo Nordisk A/S | Anticuerpos anti-NKG2A y usos de los mismos |
| AU2011352205B2 (en) | 2010-12-31 | 2016-06-16 | Bioatla, Llc | Express humanization of antibodies |
| EP3763740A1 (de) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit-antikörper und verwendungen davon |
| JP5997151B2 (ja) | 2011-06-30 | 2016-09-28 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| US9498543B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| EP3065773A1 (de) | 2013-11-05 | 2016-09-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Humane neutralisierende anti-kit-antikörper und verwendungen davon |
| CR20160534A (es) | 2014-04-27 | 2017-04-25 | Ccam Biotherapeutics Ltd | Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1) |
| US10786578B2 (en) * | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| GB201802201D0 (en) | 2018-02-09 | 2018-03-28 | Ultrahuman Five Ltd | Binding agents |
-
2018
- 2018-02-09 GB GBGB1802201.2A patent/GB201802201D0/en not_active Ceased
- 2018-04-20 GB GBGB1806468.3A patent/GB201806468D0/en not_active Ceased
-
2019
- 2019-02-11 JP JP2020533287A patent/JP7449861B2/ja active Active
- 2019-02-11 CN CN202311493358.8A patent/CN117510635A/zh active Pending
- 2019-02-11 WO PCT/EP2019/053331 patent/WO2019155067A1/en active Application Filing
- 2019-02-11 CA CA3085246A patent/CA3085246A1/en active Pending
- 2019-02-11 CN CN201980011298.7A patent/CN111683970B/zh active Active
- 2019-02-11 AU AU2019219312A patent/AU2019219312B2/en active Active
- 2019-02-11 SG SG11202005357QA patent/SG11202005357QA/en unknown
- 2019-02-11 EP EP19706418.1A patent/EP3749694A1/de active Pending
- 2019-07-25 US US16/521,793 patent/US10611838B2/en active Active
-
2020
- 2020-03-13 US US16/818,149 patent/US11377493B2/en active Active
- 2020-06-25 IL IL275657A patent/IL275657A/en unknown
-
2022
- 2022-07-01 US US17/810,423 patent/US20230212285A1/en active Pending
-
2023
- 2023-10-17 AU AU2023251427A patent/AU2023251427A1/en active Pending
- 2023-11-02 JP JP2023188151A patent/JP2024009004A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019155067A5 (de) | ||
| JPWO2019185717A5 (de) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP7314146B2 (ja) | 細胞傷害誘導治療剤 | |
| JP2020531048A5 (de) | ||
| KR101374454B1 (ko) | 회합제어에 의한 폴리펩티드 제조방법 | |
| US20240239890A1 (en) | Cytotoxicity-inducing therapeutic agent | |
| JP2019500892A5 (de) | ||
| JP2019500891A5 (de) | ||
| JP2019501883A5 (de) | ||
| JP2016536020A5 (de) | ||
| JP2017149720A5 (de) | ||
| AU2017200999A1 (en) | Cytotoxicity-inducing therapeutic agent | |
| JP2018506961A5 (de) | ||
| JP2020534351A5 (de) | ||
| US20210054076A1 (en) | Cytotoxicity-inducing therapeutic agent | |
| JP2020514277A5 (de) | ||
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| RU2019125975A (ru) | Связывающие агенты | |
| CA3036912A1 (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| JP2020521504A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2010509931A5 (de) | ||
| JP2020513759A5 (de) | ||
| JPWO2019224717A5 (de) | ||
| AU2019254537A1 (en) | Antibodies for chelated radionuclides |